Background: The identification of the signals that should be provided by antigen-presenting cells (APCs) to induce a CD8 + T cell response in vivo is essential to improve vaccination strategies using antigen-loaded APCs. Although dendritic cells have been extensively studied, the ability of other APC types, such as B cells, to induce a CD8 + T cell response have not been thoroughly evaluated.
Introduction
T cells recognize via their specific T cell receptor (TCR) a peptidic fragment of the antigen (Ag) in association with MHC molecules presented at the surface of Ag-presenting cells (APCs). Following Ag encounter, T cells undergo massive proliferation and differentiate into effector T (Te) cells. After elimination of the pathogen or tumor, most Te cells die by apoptosis while a few differentiate into memory T (Tm) cells providing long term protection against re-infection or tumor relapse. The success of vaccination is dependent on the generation and long-term maintenance of functional Ag-specific Tm cells. However, little is known about the signals that should be provided by APCs to promote Tm cell development.
Efficient priming of naïve CD8 + T cells depends on the provision by APCs of three key signals to T cells. First, APCs should present, embedded in their major histocompatibility complex (MHC) class I molecules, a peptidic fragment of the Ag. Second, co-stimulation via CD80 and CD86 expressed by APCs is essential to induce naïve CD8 + T cell response. Third, inflammatory signals, such as interleukin (IL)-12 or type I interferons (IFNs), are necessary to induce an optimal response of CD8 + T cells [1] . Furthermore, several other molecules expressed by APCs have been shown to influence CD8 + T cell response. Among those, cytokines, costimulatory molecules of the tumor necrosis factor (TNF) family, Notch ligands and adhesion molecules have been shown to play a role at different stages of the T cell response. However, the exact signals that should be provided by APCs to induce efficient generation of CD8 + Tm cells are still unknown. This knowledge is crucial to improve vaccination strategy and to better define the type of APCs that should be used for therapeutic vaccination.
Several studies have shown that vaccination with Ag-pulsed dendritic cells (DCs) is very efficient to promote the development of functional and long-lived CD8 + Tm cells [2, 3] . Very interestingly, CD8
+ Tm cell generation is accelerated with DC vaccination when compared to immunization with live pathogens [2] . This is mostly due to the low level of inflammation that promotes the formation of memory precursor effector cells (MPECs) expressing high level of CD127 and low level of KLRG1 [2] [3] [4] . The excellent Ag presentation capability of DCs and their powerful ability to prime naïve T cells have put these cells at the forefront of therapeutic vaccination strategies to treat cancer or infected patients. However, this approach has not been extremely successful yet. Furthermore, DCs are present in very low number in peripheral blood which limits their use [5] . Therefore, investigating the ability of other more abundant APC types, such as activated B cells, to induce a CD8 + T cell response might help to design better vaccination strategy and to gain knowledge about the signals that APCs should provide for the development of CD8 + Tm cells. Little is known on the potential of other APCs, such as B cells, to induce the generation of Te and Tm cells. Previous studies have shown that immunization with naïve resting B cells induce T cell unresponsiveness in naïve CD4
+ [6] [7] [8] [9] [10] [11] [12] and CD8 + T cells [11] . This tolerance induction probably results from poor expression of costimulatory molecules by naïve B cells. Although activation of B cells with LPS induced expression of CD80 and CD86, this was not sufficient to induce T cell priming [11, 13] indicating that other signals should be provided to B cells. More recent studies have shown that human CD40-activated B (CD40-B) cells are very good at inducing Ag-specific CD4
+ and CD8 + T cell response in vitro [14] [15] [16] [17] . Indeed, these CD40-activated B cells express high levels of costimulatory ligands, major histocompatibility (MHC) class I and class II molecules [14, 18, 19] , CD62L and have the ability to migrate to secondary lymphoid organs [19] [20] [21] . These characteristics suggest that these cells might be very efficient to induce the response of naïve CD8 + T cells in vivo. In addition, the possibility to expand these cells in large number from peripheral blood [20] renders them even more attractive to use in vaccination protocol.
In this manuscript, we have characterized the ability of CD40-B cells, stimulated or not with Toll-like receptor (TLR) agonists to induce the response of naïve CD8 + T cells in vivo. Our results show that CD40-B cells can directly present Ag to naïve CD8 + T cells to induce the generation of potent effectors able to secrete cytokines, kill target cells and control a Listeria monocytogenes (Lm) infection. However, CD40-B cell immunization did not lead to the proper formation of CD8 + Tm cells. Although maturation of CD40-B cells with TLR agonists increased the number of Ag-specific T cells generated it did not promote the development of CD8 + Tm cells. Understanding why CD40-B cell immunization is defective for the generation of Tm cells and gaining new insights about signals that should be provided by APCs are key steps before translating the use of CD40-B cell for therapeutic vaccination.
Materials and Methods

Mice
B6SJL, C57BL/6 and OT-1 [22] mice were bred at the Maisonneuve-Rosemont Hospital Research Center facility. Bm1 mice (B6.C-H2K bm1 /ByJ) were purchased from the Jackson Laboratory. Mice were housed in a pathogen-free environment and treated in accordance to the Canadian Council on Animal Care guidelines. Our animal protocol (number: 2007-36) was approved by the Hospital Maisonneuve-Rosemont Council on Animal Care.
B cell and DC cultures
For B cell culture, lymphocytes were isolated on a FICOLL gradient from male C57BL/6 or B6SJL spleen followed by a 4 days culture on irradiated fibroblasts stably transfected with the CD40L cDNA (3T3-CD40L) [23] to generate CD40-B cells. Bone-marrow derived DC were generated as previously described [3] . The day before harvesting, lipopolysaccharide (LPS) (1 mg/ml) or CpG-DNA (2 mM) was added to cultures. The ovalbumin (OVA) 257-264 peptide (SIINFEKL) or an irrelevant peptide (SIYRYYGL) (Midwest biotech) was loaded overnight on DCs (2 mg/ml) and B cells (4 mg/ml) on the last day of culture.
Immunization and analysis of T cell response
Two days after adoptive transfer of 10 6 OT-1 T cells (CD45.2 + ; from female mice) into female B6SJL mice (CD45.1 + ), recipients were immunized i.v. with 0.5-2610 6 DCs or 2-6610 6 CD40-B cells (from male mice to induce a CD4 T cell response against the male minor histocompatitbility antigen HY [24] ) as indicated in figure legends. The presence of Te (d4 post-immunization) and Tm (d30/45 post-immunization) cells were evaluated in the same mouse by sequential removal of superficial lymph nodes as described previously [3] . The presence of Tm cells in tertiary sites and effector functions were analyzed as previously described [3] . Te and Tm cells were identified by flow cytometry as being CD8 
Abs, cytometry, and cell sorting
Anti-CD86 (GL-1), -CD8 (53-6.7), -Ly6C (AL-21), CD122 (5H4) and -Bcl-2 (A19-3) were purchased from BD Biosciences. Anti-H2-K b (AF6-88.5), -CD40 (IC10), -CD45.2 (104), -CD44-APC-Cy7 (1M7), -CD8 (53-6.7), CD19 (6D5), -CD11c (N418), -NK1.1 (PK136), CD27 (LG.3A10), CD80 (16-10A1), CD43 (1B11) and -IL-2 (JES6-5H4) were purchased from Biolegend. Anti-I-A b (28-16-8S), -CD62L (MEL-14) and -CD11b (M1/ 70.15) were purchased from Caltag Laboratories. Anti-CD127 (A7R34), -Eomes-Alexa-647 (Dan11mag) and -granzyme B-PE (16G6) were purchased from eBioscience. Anti-Bcl-6-PE (7D1) and -T-bet-PE (4B10) were purchased from Santa Cruz Biotechnology. Anti-IFN-c-FITC (XMG1.2) was purchased from Invitrogen. OVA peptide loading on K b MHC was measured by staining with the 25-D1.16 Ab [25] followed by staining with a rat antimouse IgG1-PE (A85-1) antibody purchased from BD Bioscience. The H2K b -OVA monomers were purchased from CANVAC tetramer core facility and tetramers were generated using extravidin-PE. Cell surface stainings and intracellular stainings for cytokine were performed as previously described [3, 26] . Bcl-6 and Eomes intracellular stainings were performed with the FoxP3 kit from eBioscience while T-bet staining was done with the cytofix/cytoperm kit from BD Bioscience. For Bcl-2 staining, cells were stained for 30 minutes in 0.1% saponin (Sigma-Aldrich) and washed twice without saponin before cell surface staining. In some experiments, CD40-B LPS cells were sorted before immunization. Cells were stained with anti-CD11b, anti-NK1.1 and anti-CD11c Abs. Negative cells (B cells) were sorted on a FACSVantage and injected into mice.
In vivo killing assay
At d4 post-immunization, equal numbers ( 10 7 ) of B6.SJL splenocytes loaded or not with the OVA peptide and differentially stained with CFSE (250 nM or 25 nM respectively) were injected i.v. into immunized mice. 4 h later, the percentage of in vivo killing was determined as described previously [27] . The percentage of specific lysis was calculated as follows: ratio = (percentage CFSE low/percentage CFSE high), and percentage of specific lysis = [12(ratio unprimed/ratio primed)]6100.
Listeria monocytogenes (Lm) challenge
Lm was grown as previously described [28] . One lethal dose (10 5 bacteria) of Lm expressing OVA was injected i.v. Three days post-infection, spleen and liver were harvested, homogenized, diluted and plated onto brain hearth infusion (BHI) plates containing streptomycin. After 24 h of incubation at 37uC, CFU/g of organ was determined.
Quantitative real-time PCR
Total RNA was isolated using TRIzol (Invitrogen). RNA were reverse transcribed into cDNA using Superscript II with oligo(dT) primers (Invitrogen) as previously described [26] . Real-time PCR were performed in triplicates using SYBR Green (Invitrogen) on an Applied Biosystems 7500 Real Time PCR system. PCR was performed with mouse Blimp-1 primers: forward, 59-ACA CAC AGG AGA GAA GCC ACA TGA-39 and reverse, 59TCG AAG GTG GGT CTT GAG ATT GCT-39. The primers for the internal control hypoxanthine guanine phosphoribosyl transferase (HPRT) were: forward, 59-CTC CTC AGA CCG CTT TTT GC-39 and reverse, 59-TAA CCT GGT TCA TCA TCG CTA ATC-39 [29] . The DC T value for each sample was determined by calculating the difference between the C T value of the target and the C T value of the endogenous reference gene (HPRT). Then, the DDC T value for each sample was determined by subtracting the mean of DC T value of the sample from the DC T value of a reference sample composed of cDNA from brain, thymus, spleen, activated splenocytes (anti-CD3 and anti-CD28), EL4 cell line, D011.10 cell line and SAMBOK cell line. The relative level of target gene expression was calculated using 2 2DDCT .
Statistical analysis
Statistical analyses for differences between groups were performed using one-way ANOVA followed by Games-Howell post-tests (3 experimental groups or more) or Student's T-test (two experimental groups). Data are presented as mean +/2 SEM. All tests were two-sided and p,0.05 was considered statistically significant.
Results
CD40-B cell immunization efficiently generates effector CD8
+ T cells but not memory
We tested if activation of B cells with CD40L and further maturation with different TLR agonists generated APCs able to induce an in vivo CD8 + T cell response. Splenocytes were activated and expanded on fibroblasts expressing CD40L and then LPS or CpG DNA was added to stimulate TLR4 or TLR9 respectively (hereafter referred to as CD40-B LPS and CD40-B CpG). CD40 engagement on B cells resulted in up-regulation of the costimulatory molecules CD80 and CD86 but CD40-B LPS cells bore a greater activated state when compared to CD40-B and CD40-B CpG cells. (Figure 1 and Figure S1 ). The expression of CD62L and CD40 was similar in all conditions ( Figure 1 and Figure S1 ). Furthermore, the expression of K b and I-A b MHC molecules was comparably up-regulated in the three groups of CD40-B cells ( Figure 1 and Figure S1 ).
Next, we evaluated the ability of our different CD40-B cell cultures to prime CD8 + T cell response in vivo. To do so, we adoptively transferred 10 6 naïve OVA-specific OT-1 CD8 + T cells followed by immunization with 2610 6 CD40-B, CD40-B CpG or CD40-B LPS cells pulsed with the OVA peptide. As shown in Figure S1 , peptide loading was equivalent in the three groups of CD40-B cells. To provide T cell help, an endogenous anti-male response by CD4 + T cells was generated by immunizing female recipients, transferred with female OT-1 T cells, with male APCs. The CD8 + T cell response obtained after CD40-B cell immunization was always compared to the one obtained with LPSactivated DCs. Our results show that immunization with CD40-B cells allows for the generation of CD8 + Te cells (Figure 2A and B). However, CpG or LPS activation of CD40-B cells increases the number of Te cells (Figure 2A and B), although 2-fold less than DC immunization. We were also able to induce the response of endogenous CD8
+ T cells (without the adoptive transfer of OT-1 T cells) to OVA using tetramer staining following CD40-B cell immunization ( Figure S2 ).
Most strikingly, CD40-B cells matured or not with TLR ligands were almost always unable to induce CD8 + Tm cell development while DC immunization led to efficient CD8 + Tm cell generation (Figure 2A-D) . Similar results were obtained in the spleen, peritoneum and bone marrow (not shown). The lack of Tm cell generation with CD40-B cell immunization is not a consequence of the reduced number of Te cells generated since Tm cells were also efficiently generated when we immunized with less DCs ( Figure S3 ), which led to the production of less effectors. In few experiments, some CD8 + Tm cells were generated following CD40-B cell immunization. However, the yield of Tm cell generation was always very low ( Figure 2C ). None of the mice immunized with CD40-B LPS or CD40-B CpG cells developed significant number of Tm cells (at least 5% of effectors; Figure 2D ) while a very low proportion of mice immunized with CD40-B cells did. These results show that TLR stimulation of CD40-B cells enhanced their in vivo priming potential which leads to an increased number of Ag-specific effectors but this was not sufficient to promote CD8 + Tm cell generation. Furthermore, we have challenged a cohort of mice where Tm cell generation was below the detection limit with Lm to confirm the lack of Tm generation. Thirty days post-immunization with CD40-B LPS cells, mice were not protected from Lm infection as shown by bacterial counts in the spleen and liver ( Figure 2E and F) . Notwithstanding, the few Tm cells that were generated in some experiments were functional as shown by their rapid recall response when challenged with Agpulsed DCs ( Figure S4) .
We have previously shown that the density of epitope presented by DCs critically affects the yield of CD8 + Tm cell generation [30] . Therefore, we have carefully compared the level of K b -OVA complexes at the surface of CD40-B cells and DCs. As shown, in Figure S1 and S5, CD40-B cells express a higher density of epitope than DCs. To definitively rule out that CD40-B cells were not presenting enough Ag, we have immunized mice with CD40-B cells loaded with more peptide and showed that this did not ameliorate the formation of CD8 + Tm cells ( Figure S5 ).
CD40-B cells directly present Ag to CD8 + T lymphocytes in vivo
At the end of the culture, we obtained an almost pure population of B cells (,95%) with few contaminating CD11c Figure 3A) . These results suggest a direct priming of CD8 + T cells by CD40-B LPS cells, but we could not exclude that B cells were providing the OVA peptide to endogenous APCs for cross-presentation. To rule out this possibility, we used Bm1 mice which express a variant of the MHC class I molecule H2-K b . The H2-K bm1 molecule has 3 amino acid substitutions in residues involved in peptide binding and TCR interaction rendering this molecule unable to present the OVA peptide to OT-1 T cells [31, 32] . Therefore, APCs from Bm1 mice are unable to cross-present the OVA peptide to the transferred OT-1 T cells allowing us to test if CD40-B cells can directly present the Ag and prime naïve CD8 + T cells. Unfortunately, this mutation is sufficient to induce rejection of transferred OT-1 T cells within 2 to 3 days [33] . To bypass this problem, we transferred into C57BL/6 or Bm1 mice 5610 6 CFSE labeled OT-1 T cells in the morning followed by LPS-stimulated CD40-B cell or DC immunization in the afternoon. CFSE dilution 2 d post-immunization in the spleen demonstrates that the Ag is directly presented by the injected CD40-B cells ( Figure 3B ). All OT-1 T cells in the Bm1 mice have proliferated, suggesting that CD40-B cells can directly present Ag to naïve CD8 + T cells.
CD40-B cell or DC vaccination generates similar effectors
To understand why CD40-B cell immunization does not lead to memory generation, we have characterized Te cell phenotype. Te cells generated following CD40-B cell or DC immunization have a similar phenotype ( Figure 4A and Figure S6 ). The level of expression of CD44, CD62L, CD27, CD122 and 1B11 were similar in the different groups indicating equivalent activation of CD8 + effectors following CD40-B cell or DC immunization ( Figure 4A ). We observed a slightly lower expression of CD127 (IL-7 receptor a chain) by effectors generated following immunization with CD40-B cells compared to DCs. Since high level of CD127 expression identifies the effectors that generate memory T cells, we have further evaluated if there was a positive correlation between the level of expression of CD127 and the yield of memory T cells. As shown in Figure 4B , there is no correlation between CD127 expression and the percentage of Tm cells generated for both CD40-B cell and DC immunizations. The lack of correlation is not surprising since more than 75% of the effectors have maintained a high level of CD127 expression ( Figure S7 ). Therefore, it is very unlikely that the deficiency of Tm cell generation with CD40-B cell vaccination is due to lower level of CD127. In our immunization conditions, we did not obtain any increase in KLRG1 expression, a marker used to identify short-lived effectors (SLECs) in inflammatory models (not shown) [4, 34] . Due to low inflammation, most of our Te cells bear a MPEC phenotype [4] . Therefore, the cell surface phenotype of effectors generated after B cell immunization does not explain the poor generation of CD8 + Tm cells. To better characterize the potential of CD40-B cell vaccination, we evaluated effector functions of OVA-specific CD8 + T cells at the peak of the response. Te cells generated after B cell or DC immunization produce similar amounts of IL-2 ( Figure 5 and Figure S6 ). All types of immunization led to IFN-c production by effectors but CD40-B CpG cell vaccination induces higher Priming of CD8production of IFN-c than immunization with CD40-B LPS cells ( Figure 5 and Figure S6 ). However, granzyme B production is lower following CD40-B cell immunization ( Figure 5 and Figure  S6 ) but this is only statistically significant for CD40-B LPS cell immunization.
CD40-B cell immunization generates cytotoxic effectors
The lower level of granzyme B production by CD8 + Te cells obtained after CD40-B cell vaccination led us to evaluate their ability to kill target cells in vivo. At d4 post-immunization, mice were injected with OVA loaded target cells and specific lysis was measured 4 h later. Te cells generated with CD40-B cell vaccination have a reduced ability to kill target cells when compared to the one obtained with DC immunization (Figure 6 A and B). The reduced cytotoxic activity of Te cells generated after CD40-B cell immunization could be a result of their lower frequency when compared to DC immunization (Figure 2) . Thus, CD40-B cell immunization generates functional cytolytic effectors.
Effectors are able to control a bacterial infection
To further assess the functionality of Te cells following CD40-B cell vaccination, we have measured their ability to control a Lm 
Enhanced contraction and reduced Bcl-6 expression by effectors following CD40-B cell immunization
Our results clearly show that both DC and CD40-B cell immunizations generate fully functional CD8 + effectors and that only Tm cell generation is impaired following CD40-B cell vaccination. To further address why effectors generated with CD40-B cell immunization did not differentiate into Tm cells, we have evaluated the extent of T cell contraction. As shown in Figure 7A , CD8 + Te cells generated with CD40-B cell immunization have a higher rate of contraction than the one generated with DC immunization. Moreover, at day 10 postimmunization, CD8
+ Te cells obtained with CD40-B cells were already almost undetectable ( Figure 7A ). The enhanced contraction of effectors generated with CD40-B cell immunization is not due to a lower expression of Bcl-2 ( Figure 7B ). The transcriptional network controlling CD8 + Tm cell generation has been partially elucidated over the last years. During CD8 + T cell response to infection, the effectors (short-lived effectors or SLECs) that will die by apoptosis expressed high level of the transcription factor T-bet while MPECs express lower amount of T-bet [4] . The level of expression of the transcription factor Eomes inversely correlates with the level of T-bet suggesting that high level of Eomes are necessary to promote MPEC development and Tm cell formation [29, 35, 36] . Furthermore, Eomes expression is needed for CD8 + Tm cell self-renewal [37] . Similarly to T-bet, the transcriptional repressor Blimp-1 controls the formation of SLECs and in its absence MPECs are preferentially generated [38, 39] . The transcriptional repressor Bcl-6 is required for CD8 + Tm cell generation but unlike T-bet, Eomes and Blimp-1 it does not contribute to effector formation [40, 41] . Furthermore, Blimp-1 represses Bcl-6 expression allowing for the differentiation of SLECs. Therefore, the balance of expression of T-bet, Blimp-1, Eomes and Bcl-6 is crucial for efficient development of CD8 + Tm cells. To elucidate why CD40-B cell immunization is not efficient to generate CD8 + Tm cells, we evaluated the expression level of these key transcription factors in Te cells (CD8 + CD45.2 + ) at the peak of the response (d4 post- 
Discussion
To better understand the signals given by different APCs, we have compared CD8
+ T cell responses generated after CD40-B cell or DC immunization. Our results clearly demonstrate that CD40-B cells can present Ag and activate naïve CD8 + T cells in vivo. It is not surprising that CD40-B cells can act as efficient APCs in vivo since CD40 stimulation leads to the up-regulation of MHC class I and II molecules, CD80 and CD86 co-stimulatory molecules allowing CD40-B cells to present Ag and provide efficient co-stimulation to naïve CD8 + T cells. Previous reports have shown that B cells are tolerogenic APCs [6] [7] [8] [9] [10] [11] [12] but they used small resting B cells lacking CD80 and CD86 expression, thus explaining why no priming occurs. In our study, we have also investigated if CD40-B cells directly present Ag to CD8 + T cells or if they only provide Ag for cross-presentation by endogenous APCs. Using Bm1 mice as recipients for vaccination, we clearly show that CD40-B cell directly act as APCs and that crosspresentation by DCs is not necessary to induce a CD8 + T cell response. Therefore, CD40-B cells are good APCs to prime naïve CD8 + T cells in vivo opening the potential for their use in vaccination.
When compared to DC, CD40-B cell vaccination generates 2 fold less effectors even after maturation with LPS or CpG. This small difference is not a clinical issue since it could be easily compensated by increasing the number of CD40-B cells used in immunization. In fact, we have observed a similar expansion of Ag-specific CD8
+ T cells when we used 3-4 times more CD40-B cells than DCs ( Figure S3 ). Increasing the number of CD40-B cells in immunization is a relevant solution because it is very easy to generate them in large numbers from small amounts of human blood. Therefore, our results suggest that CD40-B cell immunization can be as good as DC immunization to generate Ag-specific CD8 + Te cells. Our results also show that further maturation of CD40-B cells with TLR agonists, CpG or LPS, increases the number of Ag-specific CD8 + T cells generated. Therefore, in vaccination protocols, it would be advantageous to activate CD40-B cells with TLR agonists to increase effector generation.
Our results also show that CD40-B cell vaccination is able to induce the proper differentiation of naïve CD8 + T cells into functional effectors. Only a minor difference was observed at the functional level, effectors obtained with CD40-B LPS cell immunization produce less granzyme B than the one obtained with DC vaccination. Although producing less granzyme B, these effectors were able to kill target cells in vivo. This indicates that CD40-B cell vaccination is able to provide all the necessary signals to generate cytolytic effectors. Furthermore, effectors generated with CD40-B cell immunization expressed similar level of IFN-c and IL-2 when compared to Ag-specific CD8 + T cells obtained with DC immunization. The production of IFN-c by effectors obtained with CD40-B cell vaccination is very interesting since IFN-c production correlates positively with clinically effective antitumor response [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] . Moreover, Te cells generated with CD40-B cell vaccination are able to control a Lm infection. Thus, our results show that CD40-B cell immunization generates functional effectors able to produce IFN-c, to kill target cells and to control bacterial infection. Therefore, the ability of CD40-B cell vaccination to produce potent effectors renders this approach of interest to induce anti-tumor T cell response in cancer patients.
It is intriguing that CD40-B cell vaccination does not generate T cell memory since most of the Te cells generated have a MPEC phenotype (CD127 To better understand why CD40-B cell vaccination is not efficient in promoting CD8
+ Tm cell generation, we evaluated the expression of T-bet, Eomes, Blimp-1 and Bcl-6 which are key transcription factors known to influence memory generation and maintenance [4, 29, [35] [36] [37] [38] [39] . No differences were observed in the expression of T-bet and Blimp-1 in Te cells obtained from CD40-B cell and DC immunizations. Since the expression level of these transcription factors control the fate between SLECs and MPECs [29, 35, 36, 38, 39, 53] , our results suggest that Te cells generated with CD40-B cell immunization are not more terminally differentiated than the ones obtained with DC immunization and that defective expression of these transcription factors are not responsible for the poor memory generation that we observed with CD40-B cell vaccination. Although effectors generated following CD40-B cell immunization express higher level of Eomes they are not able to differentiate into Tm cells suggesting that high level of Eomes is not sufficient to promote CD8 + Tm cell development. However, Te cells generated with CD40-B cell immunization express lower amount of the transcriptional repressor Bcl-6, known to control CD8 + Tm cell development [40, 41] , than effectors generated with DC immunization. Therefore, it is possible that this small (25%) reduction in Bcl-6 expression is responsible for the poor development of CD8 + Tm cells following CD40-B cell vaccination. Further studies should reveal whether reduced Bcl-6 expression is solely responsible for the lack of CD8 + Tm cell generation or if improper induction of other transcription factors contributes to defective formation of CD8 + Tm cells with CD40-B cell immunization.
In our hands, no protection was achieved when mice were challenged with Lm at d30 post-immunization. This is in contrast with the results of Vanden Bush et al [54] reporting successful protection from Lm infection 30 d after CD40-B cell vaccination. However, in their manuscript, they only look at protection and did not enumerate the number of CD8 + Tm cells generated. It is possible that a very low number of CD8 + Tm cells are generated with CD40-B cell vaccination rendering their detection difficult. However, it is very clear from our results that in some experiments, but not all, CD8
+ Tm cells are generated and are able to respond to a recall immunization with DCs. Therefore, it is possible that mice will be protected from a Lm challenge when few CD8 + Tm cells are produced. The difference might also be explained by the protocol used to generate CD40-B cells. Indeed, Bishop's team used CD40-B cells that spent only one day in culture [54] while we used cells cultured for 4 days. We believe that our protocol is closer to what is currently developed for human B cell expansion [15, 20] . Thus, it will be primordial to determine if the culture regimen impacts the ability of CD40-B cells to activate the immune system.
Although CD8 + Tm cell generation is not optimal with CD40-B cell vaccination such an approach might be viable in vaccination strategy if a boosting regimen is included. Indeed, our preliminary results suggest that it is possible to further re-expand the few Tm cells that were generated in some experiments.
Understanding why CD40-B cell immunization does not promote efficient CD8 + Tm cell differentiation will help our understanding of the mechanisms regulating CD8
+ Tm cell generation and should allow for improvement of the APC potential of CD40-B cells. Furthermore, the ability of CD40-B cell vaccination to generate cytolytic effectors producing IFN-c might be very beneficial for therapeutic vaccination. + T cells generated after CD40-B cell immunization. A. Phenotype of OVA-specific CD8 + effector T cells. 10 6 female OT-1 cells were adoptively transferred into B6SJL female mice followed by immunization with 2610 6 CD40-B cells, matured or not with LPS (1 mg/mL) or CpG-DNA (2 mM) and loaded with 4 mg/mL SIINFEKL (OVA) or an irrelevant peptide (IRR). As a reference recipients were immunized with 2610 6 DCs matured with LPS and loaded with OVA peptide. Figure S7 The majority of effectors generated with CD40-B cell immunization express high level of CD127. 
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